Tharimmune Inc., a biotechnology company focusing on therapeutic candidates for inflammation and immunology, has announced key appointments to its executive leadership and board. Sireesh Appajosyula has been appointed as Chief Executive Officer, transitioning from his previous role as Chief Operating Officer. Vincent LoPriore has been named Executive Chairman of the Board, having served as a board member since April 2025. Additionally, James Gordon Liddy has joined the Board of Directors. These changes aim to advance the company's strategic initiatives and pipeline development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.